FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.13  |  FHIR Version n/a  User: [n/a]

698091001: canakinumab (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2014. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
2971724019 Canakinumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
2971764015 Canakinumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
729281000241115 canakinumab (substance) fr Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT Common French translation module (core metadata concept)
797311000172110 canakinumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Common French translation module (core metadata concept)


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Canakinumab (substance) est un(e) (attribut) Monoclonal antibody agent (substance) false Inferred relationship Some
Canakinumab (substance) est un(e) (attribut) Interleukin 1 receptor antagonist true Inferred relationship Some
Canakinumab (substance) est un(e) (attribut) Monoclonal antibody (substance) true Inferred relationship Some
Canakinumab (substance) Has disposition (attribute) Interleukin 1 receptor antagonist (disposition) true Inferred relationship Some
Canakinumab (substance) est un(e) (attribut) Immunologic agent (substance) true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Canakinumab only product a pour principe actif (attribut) True Canakinumab (substance) Inferred relationship Some 1
Canakinumab-containing product in parenteral dose form a pour principe actif (attribut) True Canakinumab (substance) Inferred relationship Some 1
Product containing precisely canakinumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) Has basis of strength substance (attribute) True Canakinumab (substance) Inferred relationship Some 1
Product containing precisely canakinumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) Has precise active ingredient True Canakinumab (substance) Inferred relationship Some 1
Product containing precisely canakinumab 150 milligram/1 vial lyophilized powder for conventional release solution for injection (clinical drug) Has basis of strength substance (attribute) False Canakinumab (substance) Inferred relationship Some 1
Product containing precisely canakinumab 150 milligram/1 vial lyophilized powder for conventional release solution for injection (clinical drug) Has precise active ingredient False Canakinumab (substance) Inferred relationship Some 1
Canakinumab only product in parenteral dose form a pour principe actif (attribut) True Canakinumab (substance) Inferred relationship Some 1
Canakinumab 150 mg powder for solution for injection vial Has precise active ingredient True Canakinumab (substance) Inferred relationship Some 1
Canakinumab 150 mg powder for solution for injection vial Has basis of strength substance (attribute) True Canakinumab (substance) Inferred relationship Some 1
Product containing canakinumab (medicinal product) a pour principe actif (attribut) True Canakinumab (substance) Inferred relationship Some 1
Canakinumab 150mg powder for injection solution (product) a pour principe actif (attribut) False Canakinumab (substance) Inferred relationship Some

Reference Sets

Canada English language reference set (foundation metadata concept)

GB English

US English

Back to Start